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INTRODUCTION
Aspirin-exacerbated respiratory diseases (AERD) refers to the 
development of bronchoconstriction and naso-ocular manifes-
tations in asthmatic individuals following the ingestion of aspi-
rin or other nonsteroidal anti-inflammatory drugs (NSAIDs).
1 
Recently, aspirin hypersensitivity has attracted a great deal of 
attention because of its association with increased asthma se-
verity, including life threatening asthma attacks and possible 
remodeling of both the upper and lower airways.
2 Twenty-five 
percent of asthma patients who required emergency mechani-
cal ventilation were aspirin intolerant.
3,4 Aspirin has been the 
most commonly used medication for pain control or as a pro-
phylactic for primary and secondary prevention of coronary ar-
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tery disease and other vascular diseases.
5 However, AERD re-
mains widely underdiagnosed in the asthmatic population due 
to insufficient awareness of the relationship of aspirin ingestion 
and asthma exacerbation. In a multicenter study in 10 Europe-
an countries including 500 patients, 15% of patients were un-
aware that they may be susceptible to aspirin intolerance and 
learned about it only after undergoing provocation tests.
6
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Purpose:  Aspirin-exacerbated respiratory disease (AERD) has attracted a great deal of attention because of its association with increased asthma 
severity. However, oral aspirin challenge (OAC) to diagnose AERD is a time-consuming procedure, and some patients experience serious complica-
tions. Thus, we evaluated diagnostic values of non-invasive clinical parameters to predict AERD in asthmatic patients.  Methods:  A total of 836 
Korean subjects were recruited from an asthma cohort. They underwent OAC, and clinical parameters including the history of aspirin hypersensitivi-
ty, nasal polyposis, and chronic sinusitis of aspirin-tolerant asthma (ATA) and AERD asthmatic patients were compared.  Results:  Significant differ-
ences (P<0.01) were found in eight parameters: age at diagnosis, body mass index, FEV1%, PC20, history of urticaria, nasal polyps, chronic sinus-
itis, and history of aspirin hypersensitivity. After logistic regression analysis based on the eight clinical parameters, nasal polyps, history of aspirin 
intolerance, sinusitis, and log [PC20 methacholine] remained significantly associated with AERD (P<0.05). The sensitivity and specificity of the his-
tory of aspirin hypersensitivity to predict AERD were 64.7% and 92.0%, respectively, and the positive and negative predictive values were 56.9% and 
94.1%, respectively. Overall, the accuracy of the test was 88.2%. The accuracy of the tests for nasal polyps and chronic sinusitis were 67.3% and 
60.4%, respectively.  Conclusions:  Among clinical parameters associated with AERD, the history of aspirin hypersensitivity has the best positive 
and negative predictive values for the oral aspirin challenge test. Because the false-positive and -negative rates were still high, additional non-inva-
sive methods are needed to reduce the rate of false outcomes.
Key Words:  Aspirin-exacerbated respiratory disease (AERD); aspirin hypersensitivity; history; nasal polyp; chronic sinusitis; oral aspirin challenge 
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The diagnosis of aspirin hypersensitivity and AERD is usually 
obvious from taking a clear history. Patients often have a histo-
ry of rhinosinusitis and moderate to severe asthma.
7,8 AERD 
typically develops in individuals according to a characteristic 
sequence of symptoms. Following ingestion of aspirin or cer-
tain NSAIDs, patients have an acute asthma exacerbation, typi-
cally within 3 hours. Bronchoconstriction can be accompanied 
by profuse rhinorrhea and periorbital edema. This progresses 
to recurrent and chronic sinusitis and frequently to nasal pol-
yposis.
9 Thus, this syndrome is characterized by the ‘aspirin tri-
ad’ syndrome of aspirin hypersensitivity, bronchial asthma, and 
nasal polyposis.
10 Chronic hyperplastic eosinophilic sinusitis is 
a fourth hallmark of AERD.
1 A fairly limited number of epide-
miological studies have offered estimates on the prevalence of 
AERD. The prevalence of aspirin hypersensitivity in adult asth-
matic patients was reported to vary depending on whether it 
was determined by clinical history alone or by challenge with 
aspirin.
6 Thus, the identification of aspirin hypersensitivity, es-
pecially cases not recognized by the patients, is essential to avoid 
the serious complication associated with this condition.
Diagnosis can be established with certainty only by provoca-
tion tests using increasing doses of aspirin. The four commonly 
used types of provocation tests are defined by the route of aspi-
rin administration: oral, bronchial (inhaled), intravenous, and 
nasal.
11 Oral aspirin challenge (OAC) is the gold standard to 
confirm the diagnosis. Nasal or bronchial provocation with ly-
sine-ASA may be a valuable alternative diagnostic tool. Both 
oral and bronchial tests have similar specificity, but the oral test 
has a somewhat higher sensitivity. However, OAC is a time-con-
suming procedure, and some cases experience serious compli-
cations. Thus, the development of non-invasive methods is nec-
essary for easy diagnosis to prevent unexpected complications 
associated with aspirin use in susceptible patients. In the pres-
ent study, we evaluated the diagnostic merits of clinical param-
eters including the well-known manifestation of aspirin hyper-
sensitivity history and nasal polyposis to predict aspirin hyper-
sensitivity in asthmatic patients.
MATERIALS AND METHODS
Subjects
Seven hundred two asthmatic patients without AERD and 134 
subjects with AERD were recruited from the Asthma Genome 
Research Center, which comprises three university hospitals in 
Korea. All subjects were Korean and gave their informed con-
sent to participate in the study. All patients were diagnosed by 
physicians and met the criteria for asthma according to the 
Global Initiative for Asthma (GINA) guidelines.
12 All patients 
had a history of dyspnea and wheezing during the previous 12 
months, plus one of the following: 1) >15% increase in forced 
expiratory volume in 1 second (FEV1) or >12% increase plus 
200 mL following inhalation of a short-acting bronchodilator, 2) 
<10 mg/mL PC20 methacholine, and 3) >20% increase in FEV1 
following 2 weeks of treatment with inhaled or systemic corti-
costeroids. Twenty-four commonly inhaled allergens were used 
for a skin-prick test. Total IgE was measured by the CAP system 
(Pharmacia Diagnostics, Uppsala, Sweden). Atopy was defined 
as a wheal reaction with a diameter of 3 mm or greater than the 
reaction to histamine. In the questionnaires designed to reveal 
the presence of aspirin hypersensitivity, questions related to 
five specific elements of aspirin hypersensitivity and NSAIDs 
(dyspnea, wheezing, nasal blockage, skin eruption, loss of con-
sciousness) were incorporated. The asthmatic patients had ex-
perienced no exacerbation of asthma or respiratory tract infec-
tion in the 6 weeks preceding OAC. OAC was performed in all 
subjects with increasing doses of aspirin using methods slightly 
modified from those described previously.
13,14 Briefly, patients 
having a history of aspirin hypersensitivity were given a dose of 
30 mg, and those with no history were started on 100 mg of as-
pirin orally. Symptoms, external signs (urticaria, angioedema, 
rhinorrhea), blood pressure, and FEV1 were documented every 
30 minutes for a period of 2 hours. In the absence of any symp-
toms or signs suggestive of adverse reaction after 2 hours, 60 mg 
or 100 mg of aspirin was administered and the same measure-
ments were repeated every hour, with doses of 450 mg given 
until the patient developed a reaction. If no reaction occurred 
within 4 hours after the final dose, the test was deemed nega-
tive. Aspirin-induced bronchospasms, as reflected by decline 
(%) in FEV1, were calculated as the pre-challenge FEV1 minus 
the post-challenge FEV1 divided by the pre-challenge FEV1. 
OAC reactions were categorized into two groups as follows: 1) a 
15% or greater decrease in FEV1 or naso-ocular reactions 
(AERD), and 2) a decrease of less than 15% in FEV1 without 
naso-ocular or cutaneous reactions (aspirin-tolerant asthma 
[ATA]).
A diagnosis of nasal polyps was made based on the presence 
of endoscopically visible nasal polyps arising from the middle 
nasal meatus. Chronic rhinosinusitis was diagnosed from pa-
tients’ documented medical histories and the haziness of the 
ethmoidal and maxillary sinuses as visualized by a simple X-ray 
of the paranasal sinuses. The protocols were approved by the 
Ethics Committee of the Soonchunhyang University Medical 
Center.
Statistical analysis
Differences in the mean values or frequencies were evaluated 
with chi square analysis for discrete variables or by indepen-
dent t-tests for continuous variables. We tested the indepen-
dent effects of the parameters that showed significant (P<0.01) 
association with aspirin hypersensitivity using conditional back-
ward logistic regression analysis. The sensitivity and specificity 
of the parameters were tested using receiver operating charac-
teristic (ROC) curves. All statistical analyses were performed 
using SPSS version 10.0 (SPSS Inc., Chicago, IL, USA).Chang et al.
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RESULTS
Comparison of clinical and laboratory parameters between 
AERD and ATA
A total of 836 subjects were recruited from the asthma cohort. 
The clinical characteristics of the study subjects are summarized 
in Table 1. The subjects with AERD had more severe broncho-
spasm following aspirin challenge as measured by percent de-
cline of FEV1 after OAC (P=1.63×10
-34). Significant differences 
(P<0.01) were found in nine parameters (Table 1): age at diag-
nosis, body mass index (BMI), FEV1%, PC20, history of urticar-
ia, nasal polyps, chronic sinusitis, and history of aspirin hyper-
sensitivity. Mean age and BMI were slightly lower in subjects 
with ATA than those with AERD (P=0.01 and P=0.006, respec-
tively). FEV1 and PC20 methacholine were also significantly 
lower in AERD than in ATA patients (P=1.66×10
-7 and P=3.95×
10
-5, respectively). Subjects with AERD had nearly double the 
frequency of nasal polyps (61.4% vs. 31.5%, P=1.31×10
-8) and 
chronic sinusitis (72.6% vs. 42.0%, P=8.06×10
-9) compared with 
those with ATA. The history of aspirin hypersensitivity was eight 
times higher in AERD patients compared with those with ATA 
(64.7% vs. 8.0%, P=6.81×10
-48). The frequency of urticaria his-
tory was also significantly higher in AERD patients compared 
with ATA patients (54.3% vs. 28.11%, P=0.002).
Evaluation of independent effects of clinical parameters on 
AERD using backward logistic regression analysis
To identify factors affecting the risk of aspirin intolerance, lo-
gistic regression analysis with a conditional backward method 
was used. Among the eight clinical parameters shown to have a 
P value <0.01 in the comparison between AERD and ATA pa-
tients, the presence of nasal polyps, a history of aspirin intoler-
ance, sinusitis, and log [PC20 methacholine] remained signifi-
cant, and these factors showed a significant association with 
AERD (P<0.05, Table 2). The ratio of individuals with nasal pol-
yposis, a history of ASA intolerance, and chronic sinusitis were 
Table 1. Clinical parameters of AERD and ATA
ATA AERD P value OR (95% CI)*
No. of subjects 702 134
Diagnosis of age 46.7±0.5 43.4±1.2 0.010  0.98 (0.97–1.00)
Sex (male, %) 32.8 41.0 0.064  1.43 (0.98–2.09)
Body mass index (kg/m
2) 24.5±0.1 23.6±0.3 0.006  0.92 (0.87–0.98)
Current smoker/ex-smoker (%) 13.2/15.4 11.2/7.5 0.032  -
FVC, % predicted 88.7±0.6 89.0±1.4 0.824  1.00 (0.99–1.01)
FEV1, % predicted 91.2±0.7 81.7±1.7 1.66×10
-7 0.98 (0.97–0.98)
PC20 methacholine (mg/mL) 8.3±0.4 4.2±0.9 3.95×10
-5 0.95 (0.92–0.98)
Total IgE in serum (IU/mL) 343.2±22.0 360.7±47.4 0.750  1.00 (1.00–1.00)
Atopy rate (positive, %) 39.6 41.0 0.754  1.06 (0.73–1.55)
Blood eosinophil (%) 12.4±6.7 6.1±0.5 0.686  1.00 (1.00–1.00)
Family history of asthma (%) 19.5 16.4 0.402  0.81 (0.49–1.33)
Urticaria (%) 28.1 45.3 0.002  2.12 (1.31–3.45)
Urticaria after OAC (%) 0.0 7.5 3.30×10
-13 0.15 (0.13–0.18)
Nasal polyps (%) 31.5 61.4 1.31×10
-8 3.45 (2.22–5.37)
Chronic sinusitis (%) 42.0 72.6 8.06×10
-9 3.66 (2.31–5.80)
History of aspirin hypersensitivity (%) 8.0 64.7 6.81×10
-48 21.19 (12.88–34.89)
% decline of FEV1 after OAC 3.2±0.2 27.6±1.4 1.63×10
-34 1.48 (1.37–1.59)
*Odds ratios were obtained using χ2 test for discrete variables and logistic regression analysis for continuous variables.
ATA, aspirin-tolerant asthma; AERD, aspirin-exacerbated respiratory disease; OR, odds ratio; CI, confidence interval; FVC, forced vital capacity; FEV1, forced expirato-
ry volume in 1 second; PC20 methacholine, provocative concentration of methacholine that causes a 20% fall in the FEV1; OAC, oral aspirin challenge.
Table 2. Statistically significant parameters after backward logistic regression analysis for AERD
Beta SE P value OR (95% CI)
Nasal polyps 0.874 0.362 1.58×10
-2 2.40 (1.18–4.87)
History of aspirin hypersensitivity 3.174 0.378 4.80×10
-17 23.90 (11.39–50.16)
Chronic sinusitis 1.453 0.402 3.04×10
-4 4.28 (1.94–9.41)
log [PC20] -0.918 0.231 7.17×10
-5 0.40 (0.25–0.63)
AERD, aspirin-exacerbated respiratory disease; SE, standard error; OR, odds ratio; CI, confidence interval. Diagnosis of AERD with Clinical Parameters
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significantly higher in AERD patients than in those with ATA. 
The logarithm of PC20 values for methacholine challenge was 
significantly lower in the AERD group than that in the ATA 
group. Although the FEV1 was significantly lower in AERD pa-
tients than in ATA patients, the difference became non-signifi-
cant after logistic regression analysis. The factor showing the 
highest association was a history of aspirin intolerance (odds 
ratio [OR]=23.9), followed by chronic sinusitis (OR=4.28), PC20 
methacholine (OR=0.4), and nasal polyps (OR=2.4).
Diagnostic value of clinical parameters for the prediction of 
AERD in asthmatic patients
We tested the sensitivity and specificity for AERD using ROC 
curves (Fig. 1). The area under the curve (AUC) of the four vari-
ables ranged from 0.672 to 0.768. The history of aspirin intoler-
ance showed the highest AUC value (0.768). A history of aspirin 
hypersensitivity was observed in 50 of 628 subjects with ATA 
(8%) and in 66 of 102 subjects with AERD (64.7%). Thus, 15.9% 
of all subjects studied had a positive history of aspirin hyper-
sensitivity. In subjects having a history of aspirin hypersensitiv-
ity (n=116), AERD was proven in 66 subjects (56.9%) by the oral 
provocation test. The other 43.1% of subjects with histories of 
aspirin hypersensitivity had negative OAC test results.
The sensitivity and specificity of a history of aspirin hypersen-
sitivity for predicting AERD were 64.7% and 92.0%, respectively 
(Table 3). The positive and negative predictive values were 56.9% 
and 94.1%, respectively. The overall accuracy of the test was 
88.2%. When nasal polyps were present, the sensitivity and 
specificity to predict AERD were 61.4% and 68.5%, respectively. 
The positive and negative predictive values when polyps were 
present were 28.1% and 89.8%, respectively. The overall accura-
cy of the test was 67.3%. The presence of chronic sinusitis pre-
dicted AERD with sensitivity and specificity of 72.6% and 58.0%, 
respectively. The positive and negative predictive values were 
25.6% and 91.4%, respectively. The overall accuracy of the test 
was 60.4%.
Diagnostic values of the clinical parameters to predict AERD 
according to the presence or absence of history of aspirin 
hypersensitivity
To identify additional parameters affecting the development 
of AERD, we compared clinical parameters between four groups: 
Table 3. Sensitivity and specificity of the clinical parameters to predict AERD in asthmatic patients
ATA AERD Total Diagnostic values
History of aspirin hypersensitivity (-)
(+)
Total
578 (79.2%)
50 (6.8%)
628 (86%)
36 (4.9%)
66 (9%)
102 (14%)
614 (84.1%)
116 (15.9%)
730 (100%)
Sensitivity=66/(36+66)=64.7%
Specificity=578/(578+50)=92.0%
+PV=66/(66+50)=56.9%
-PV=578/(578+36)=94.1%
Accuracy=(578+66)/730=88.2%
Nasal polyposis (-)
(+)
Total
345 (57.0%)
159 (26.3%)
504 (83.3%)
39 (6.5%)
62 (10.2%)
101 (16.7%)
384 (63.5%)
221 (36.5%)
605 (100%)
Sensitivity=62/(39+62)=61.4%
Specificity=345/(345+159)=68.5%
+PV=62/(62+159)=28.1%
-PV=345/(345+39)=89.8%
Accuracy=(345+62)/605=67.3%
Chronic sinusitis (-)
(+)
Total
309 (48.4%)
224 (35.1%)
533 (83.5%)
29 (4.5%)
77 (12.0%)
106 (16.5%)
338 (52.9%)
301 (47.1%)
639 (100%)
Sensitivity=77/(29+77)=72.6%
Specificity=309/(309+224)=58.0%
+PV=77/(77+224)=25.6%
-PV=309/(309+29)=91.4%
Accuracy=(309+77)/639=60.4%
ATA, aspirin-tolerant asthma; AERD, aspirin-exacerbated respiratory disease; +PV, positive predictive value; -PV, negative predictive value.
Test variable(s)  Area  SE  Asymptotic 
Sig. 
Asymptotic 95% CI 
Lower   Upper  
Nasal polyposis  0.672 0.038 1.25×10
-5  0.598 0.746
History of aspirin hypersensitivity  0.768 0.039 1.09×10
-11  0.691 0.844
Chronic sinusitis  0.695 0.034 7.55×10
-7  0.629 0.761
-log[PC20]  0.682   0.035 3.95×10
-6  0.613 0.750
SE, standard error; CI, confidence interval.
Fig. 1. Receiver operating characteristic curve of relative risk scores and the 
area under the curve of parameters.
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ATA groups and AERD groups with or without a history of aspi-
rin hypersensitivity. As shown in Table 4, ATA subjects with a 
history of aspirin hypersensitivity had a higher female propor-
tion, PC20 value, and FEV1% than those in the AERD group. In 
contrast, AERD subjects without a history of aspirin hypersen-
sitivity showed lower FEV1% and PC20 values than did those in 
the other groups.
Additionally, we analyzed the clinical parameters related to 
AERD in asthmatic patients with or without a history of aspirin 
hypersensitivity using backward logistic regression analysis (Ta-
ble 5). Among patients without a history of aspirin hypersensi-
tivity, the ratio of individuals with chronic sinusitis was signifi-
cantly higher in AERD patients than in ATA subjects (OR=4.95, 
P=0.0056). Furthermore, the logarithm of PC20 values for 
methacholine challenge was significantly lower in the AERD 
group than in the ATA group (OR=0.39, P=0.0016). In contrast, 
the ratio of patients with nasal polyposis was significantly high-
er in AERD patients than in ATA patients without a history of 
aspirin hypersensitivity (OR=11.54, P=0.0019).
In the asthmatic patients without a history of aspirin hyper-
sensitivity, the sensitivity and specificity of the presence of 
chronic sinusitis to predict AERD were 81.3% and 58.4%, re-
spectively (Table 6). The positive and negative predictive values 
were 11.5% and 97.9%, respectively. The overall accuracy of the 
test was 59.8%. When patients had a history of aspirin hyper-
sensitivity, the sensitivity and specificity of the presence of na-
sal polyposis to predict AERD were 68.0% and 64.9%, respec-
tively. The positive and negative predictive values were 72.3% 
and 60.0%, respectively. The overall accuracy of the test was 
66.7% (Table 6).
Function for calculating relative risk score to predict AERD in 
asthmatic patients
Using the beta value of each parameter, we calculated the rel-
ative risk score for individual subjects as follows: Σ (beta for 
variables×dummy values of clinical parameter)=0.874×nasal 
polyp+3.174×history of aspirin hypersensitivity+1.453×si-
nusitis+(-0.918)×log [PC20 methacholine]. The mean and 
standard deviation of this score were 3.70±1.74 and 0.69±1.46 
in the AERD and ATA groups, respectively (t=12.91, df=71.84 
Table 4. Comparisons of clinical parameters according to AERD status and history of aspirin hypersensitivity
ATA w/o history ATA w/ history AERD w/o history AERD w/ history P value*
No. of subjects 578 50 36 66
Diagnosis of age 46.6±0.6 46.5±1.6 45.3±2.4 40.4±1.7 0.008 
Sex (male, %) 34.6 16.0 44.4 40.9 0.016 
Body mass index (kg/m
2) 24.6±0.1 23.4±0.5 23.9±0.5 23.1±0.4 0.001 
Current smoker/ex-smoker (%) 14.7/17 6/10 16.7/8.3 12.1/9.1 0.347 
FVC, % predicted 88.4±0.6 90.8±2.1 87.7±1.8 90.5±2.1 0.511 
FEV1, % predicted 91.4±0.8 93.7±2.5 81.2±3.1 83.2±2.6 9.3×10
-5
PC20 methacholine (mg/mL) 7.8±0.4 9.9±1.6 1.6±0.4 5.2±1.4 2.65×10
-4
Total IgE in serum (IU/mL) 332.2±23 394.5±110.8 388.1±91.4 315.1±66.7 0.811 
Atopy rate (positive, %) 42.9 24.0 41.7 45.5 0.067 
Blood eosinophil (%) 13.9±8.2 5.4±0.8 8.1±1.1 5.3±0.5 0.969 
Family history of asthma (%) 22.3 16.0 27.8 18.2 0.505 
Urticaria (%) 26.0 46.0 33.3 51.4 3.55×10
-4
Urticaria after OAC (%) 0.0 0.0 8.3 10.6 1.15×10
-13 
Nasal polyps (%) 30.3 35.1 55.2 68.0 2.67×10
-7
Chronic sinusitis (%) 41.6 37.8 81.3 71.7 1.33×10
-7
% decline of FEV1 after OAC 3.6±0.2 3.9±0.7 31.2±2.1 28.4±1.7 1.25×10
-160
*The P values were obtained using χ2 test for discrete variables and one-way ANOVA for continuous variables.
AERD, aspirin-exacerbated respiratory disease; ATA, aspirin-tolerant asthma; FVC, forced vital capacity; FEV1, forced expiratory volume in 1 second; PC20 methacho-
line, provocative concentration of methacholine that causes a 20% fall in the FEV1; OAC, oral aspirin challenge. 
Table 5. Statistically significant parameters after backward logistic regression analysis for AERD according to the presence of history of aspirin hypersensitivity 
Group Parameters Beta SE P value OR (95% CI)
History (-) Chronic sinusitis 1.600 0.578 0.0056 4.95 (1.60–15.38)
log [PC20] -0.932 0.295 0.0016 0.39 (0.22–0.70)
History (+) Nasal polyposis 2.446 0.787 0.0019 11.54 (2.47–53.95)
AERD, aspirin-exacerbated respiratory disease; SE, standard error; OR, odds ratio, CI, confidence interval.Diagnosis of AERD with Clinical Parameters
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and P=2.08×10
-20, Fig. 2). The ROC curve for the risk score 
showed an AUC of 0.9, which was the highest value among all 
combinations of parameters (Fig. 3).
Considering the difference and standard deviations, we de-
fined a cut-off value for AERD prediction at 2.06. Then, we com-
pared the ratio of AERD and ATA individuals showing risk scores 
above the cut-off value. As shown in Table 7, the ratio of subjects 
showing a positive score was significantly higher in the AERD 
than that in the ATA group (OR: 16.62, P=2.19×10
-24). The sen-
sitivity and specificity of the risk scores for AERD prediction 
were 0.787 and 0.818, respectively. The positive and negative 
predictive values were 0.369 and 0.966, respectively. The overall 
accuracy of the test was 0.814.
Table 7. Sensitivity and specificity of the relative risk score to predict AERD
Status
Relative risk score
P value OR (95% CI)
<2.06 (negative) >2.06 (positive) Total
ATA 369 (81.8%) 82 (18.2%) 451 (100%) 2.19×10
-24  16.62 (8.61–32.08) 
AERD 13 (21.3%) 48 (78.7%) 61 (100%)
OR, odds ratio; CI, confidence interval; ATA, aspirin-tolerant asthma; AERD, aspirin-exacerbated respiratory disease.
Table 6. Sensitivity and specificity of the clinical parameters to predict AERD according to the presence of history of aspirin hypersensitivity
Group Parameter Status ATA AERD Total Diagnostic values
History (-) Chronic sinusitis (-)
(+)
Total
282 (54.8%)
201 (39.0%)
483 (93.8%)
6 (1.2%)
26 (5.0%)
32 (6.2%)
288 (55.9%)
227 (44.1%)
515 (100%)
χ2=19.13, df=1, P value=1.21×10
-5
Sensitivity=26/(6+26)=81.3%
Specificity=282/(282+201)=58.4%
+PV=26/(26+201)=11.5%
-PV=282/(282+6)=97.9%
Accuracy=(282+26)/515=59.8%
History (+) Nasal polyposis (-)
(+)
Total
24 (27.6%)
13 (14.9%)
37 (42.5%)
16 (18.4%)
34 (39.1%)
50 (57.5%)
40 (46.0%)
47 (54.0%)
87 (100%)
χ2=9.25, df=1, P value=4.37×10
-3
Sensitivity=34/(16+34)=68.0%
Specificity=24/(24+13)=64.9%
+PV=34/(13+34)=72.3%
-PV=24/(24+16)=60.0%
Accuracy=(24+34)/87=66.7%
ATA, aspirin-tolerant asthma; AERD, aspirin-exacerbated respiratory disease; +PV, positive predictive value; -PV, negative predictive value.
Fig. 2. The comparison of relative risk scores between aspirin-tolerant asthma 
(ATA) and aspirin-exacerbated respiratory disease (AERD). The relative risk 
scores were calculated using the following function: 0.874×nasal pol-
yp+3.174×history of aspirin intolerance+1.453×sinusitis+(-0.918)×log [PC20 
methacholine].
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Fig. 3. Receiver operating characteristic curve for relative risk score.Chang et al.
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DISCUSSION
In the present study, we evaluated clinical parameters as diag-
nostic tools to predict AERD. When clinical parameters were 
compared between the subjects with AERD and those with 
ATA, significant differences were found for eight parameters in-
cluding age, BMI, FEV1%, PC20, urticaria, nasal polyps, chronic 
sinusitis, and history of aspirin hypersensitivity. A decline in 
FEV1 after aspirin provocation was not used as a covariate be-
cause it is a determinant for AERD. To exclude the interactions 
among the factors, a logistic regression analysis using the con-
ditional backward method was applied. Among the eight clini-
cal parameters, the presence of nasal polyps, a history of aspi-
rin hypersensitivity, chronic sinusitis, and log [PC20 methacho-
line] remained significantly associated with AERD. Among these 
parameters, the most highly associated parameter was a histo-
ry of aspirin hypersensitivity, followed by chronic sinusitis 
(OR=4.28), PC20 methacholine (OR=0.4), and nasal polyps 
(OR=2.4).
A history of aspirin hypersensitivity, chronic sinusitis, and na-
sal polyps has been described as the most important pattern of 
clinical parameters since the initial definition of the aspirin tri-
ad
10 and AERD
1. However, the presence of a positive clinical 
history varies widely across populations.
6 Based on patients’ 
histories alone, the incidence of aspirin sensitivity in Caucasian 
adults with asthma is 3-5%, but this percentage doubles or tri-
ples when adult asthmatic patients are prospectively challenged 
with aspirin.
15-19 In an unselected Caucasian asthma population 
assessed by a meta-analysis, aspirin- and NSAID-induced hy-
persensitivity was shown to be 2.7% by verbal history only, in 
contrast to the 21.1% shown by the oral provocation test. In a 
preselected population with a history of aspirin-induced asth-
ma, the incidence of aspirin- and NSAID-induced hypersensi-
tivity was shown to be 12.2% by verbal history only, in contrast 
to the 29.5% identified by oral provocation test.
20 In the present 
study, 15.9% of the total population studied had a positive his-
tory of aspirin hypersensitivity. In subjects having an aspirin 
hypersensitivity history (n=116), AERD was shown in 66 sub-
jects (56.9%) by the OAC. These data indicated that the frequen-
cy of a history of aspirin hypersensitivity was markedly higher 
in Korean asthmatic patients in the present study compared 
with Caucasians. One possible explanation for this observation 
is that the study subjects were all patients with asthma. Several 
reports suggest that the prevalence of aspirin hypersensitivity 
increases significantly in populations with nasal polyposis, si-
nusitis, atopy, or asthma.
15,19 Even in asthmatic patients, the 
prevalence of AERD is known to vary according to severity and 
subtype.
21 Additionally, because the development and patho-
physiology of AERD are considered to be dependent on genetic 
factors, the proportion of subjects with a history of AERD in a 
study population could be affected by genetic and racial differ-
ences.
Interestingly, 43.1% of the subjects with an aspirin hypersen-
sitivity history had a negative OAC test result. This relationship 
indicates a very high ratio of false positivity associated with a 
history of aspirin hypersensitivity. This finding prompted us to 
estimate the diagnostic values of these clinical parameters. We 
applied ROC curves to test the sensitivity and specificity for as-
pirin hypersensitivity in asthmatic patients. Although the AUC 
of the four variables was statistically significant, the history of 
aspirin intolerance had the highest AUC value. Because the val-
ue of PC20 methacholine is continuous, this parameter was not 
analyzed for diagnostic sensitivity and specificity.
A history of aspirin hypersensitivity has low diagnostic sensi-
tivity for aspirin hypersensitivity but the highest value for diag-
nostic specificity. Thus, the accuracy ratio was 88.2%. Interest-
ingly, the positive predictive ratio was 56.9%. This result indi-
cates that more than 40% of subjects with a history of aspirin 
hypersensitivity do not respond to aspirin challenge. The nega-
tive predictive ratio was 94.1%. This finding indicates that more 
than 6% of subjects having no history of aspirin hypersensitivity 
positively respond to aspirin challenge. A European survey 
showed that 15% of provocation-test-proven AERD patients 
were entirely unaware that they had aspirin intolerance.
6 Thus, 
the 6% negative predictive ratio from our results was lower than 
that found in European populations.
The presence of nasal polyps and chronic sinusitis showed 
lower positive and negative predictive values compared with a 
history of aspirin hypersensitivity. Thus, among the parameters 
we studied, a history of aspirin hypersensitivity showed the best 
accuracy ratio. However, there was still a 40% false-positive and 
a 6% false-negative rate when predictions were based on the 
presence of a history of aspirin hypersensitivity.
Although the FEV1 was significantly lower in AERD patients 
compared with ATA patients in the present study, the difference 
was not significant after logistic regression analysis. The hyper-
reactive airway and low FEV1 associated with AERD may reflect 
the severity of asthma in subjects with AERD.
2 A history of urti-
caria was more frequently observed in AERD. However, after 
multiple regression analysis, the significant association with 
AERD disappeared. This result may reflect the effects of more 
strongly associated parameters including a history of aspirin in-
tolerance, chronic sinusitis, nasal polyps, and PC20 methacho-
line.
Comparisons between groups according to AERD status and 
AERD history (Table 4) showed that ATA subjects with a history 
of aspirin hypersensitivity had higher FEV1% values than did 
those in the AERD groups, which suggests that a subject with a 
lower FEV1% is more likely to have a positive response to the 
OAC test. In contrast, AERD subjects without a history showed 
lower PC20 and FEV1% values than those of the other groups, 
which suggests that a subject having airway hyperreactivity or 
reduced pulmonary function could be more susceptible to weak 
bronchospasms induced by the OAC test and therefore show a Diagnosis of AERD with Clinical Parameters
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positive OAC result. Thus, these observations suggest that bron-
choconstriction induced by the OAC test may be partially de-
pendent on basal FEV1% and PC20 values. We also found that 
chronic sinusitis could be an additional predictor of AERD in 
subjects without a history of aspirin intolerance, and on other 
hand, nasal polyposis could be an additional predictor in sub-
jects with an history of aspirin hypersensitivity (Tables 5 and 6). 
These results suggest that the absence of a history of a aspirin 
hypersensitivity and chronic sinusitis could be useful in pre-
dicting negative results on an OAC test and that a history of as-
pirin hypersensitivity and the presence of nasal polyposis could 
be helpful in identifying OAC-positive subjects.
To establish an integrating function to predict the results of 
OAC, we defined the relative risk score for AERD using the beta 
values obtained by logistic regression analysis for nasal polypo-
sis, history of aspirin hypersensitivity, chronic sinusitis, and 
PC20 methacholine values (Figs. 2 and 3). The calculated risk 
score was very significantly higher in AERD patients compared 
with that in ATA patients, and the AUC of the score was 0.9 for 
each parameter. Furthermore, the sensitivity, specificity, and 
accuracy of the risk score for AERD prediction were 0.787, 0.818, 
and 0.814, respectively. These results suggest that a combina-
tion of parameters could be useful for predicting results of the 
OAC test. However, false-positive and -negative values were rel-
atively high, at 0.16 and 0.025, respectively. Although this ob-
servation means that a combination of parameters is hard to 
apply to the prediction of AERD in clinical practice, the analysis 
of these parameters can provide basic information for develop-
ing non-invasive methods to diagnose AERD.
Several studies have aimed to develop non-invasive methods 
for easier diagnosis of AERD. In peripheral blood, flow-cyto-
metric determination of basophil activation has been proposed 
for in vitro diagnosis of NSAID hypersensitivity syndrome.
22 Ga-
lectin -10 mRNA
23 and plasma eotaxin 2
24 have been shown to 
be elevated in subjects with AERD compared with those with 
ATA. Several proteomic candidates have been found to be asso-
ciated with an increased risk of AERD.
25 Urine leukotriene E4 
and 9alpha 11beta in exhaled breath condensate showed a high 
sensitivity and specificity for discriminating between the two 
groups.
26 Many genetic variants in the arachidonate pathway
27-30 
and immune and inflammatory pathways
14,31,32 seem to be in-
volved in the development of AERD. However, future studies 
must determine whether these biomarkers are superior to clin-
ical parameters such as history of aspirin hypersensitivity.
In summary, we evaluated the diagnostic value of clinical pa-
rameters including the well known manifestation of aspirin hy-
persensitivity history, nasal polyposis, and chronic sinusitis to 
predict AERD in asthmatic patients. Among these parameters, 
a history of aspirin hypersensitivity has the best positive and 
negative predictive values for forecasting the outcome of the 
positive aspirin challenge test, demonstrating an overall accu-
racy of 88.2%. However, false-positive and -negative rates were 
still high. Thus, additional non-invasive methods are needed to 
reduce the errors in the use of these parameters as diagnostic 
tools.
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